3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AU2015205858A1
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
AU2015201850A1
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
TW201620875A
Cyclopropylamines as lsd1 inhibitors
AU2014346647A1
Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
AU2014218443A1
Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
AU2014253798A1
Bicyclic heterocycles as FGFR inhibitors
NZ749437A
Processes and intermediates for making a jak inhibitor
TW202019428A
USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS
NZ710079A
Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
PE20200175A1
SUSTAINED RELEASE RUXOLITINIB DOSAGE FORMS
AU2013337824A1
Tricyclic fused thiophene derivatives as JAK inhibitors
NZ702747A
Substituted tricyclic compounds as fgfr inhibitors
HK1168090A1
Heteroaryl substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as janus kinase inhibitors janus [23-b][23-b]
HUE030869T2
Heterocyclylamines as pi3k inhibitors
AU2011329734A1
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
ME02445B
Topical formulation for a jak inhibitor
EA036970B1
USE OF {1-{1-[3-FLUORO-2-(TRIFLUOROMETHYL)ISONICOTINOYL]PIPERIDINE-4-YL}-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDINE-4-YL)-1H-PYRAZOL-1-YL]AZETIDINE-3-YL}ACETONITRILE IN TREATING JAK1-ASSOCIATED DISEASES
KR20180126619A
Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CA3064247A1
Janus kinase inhibitors for treatment of dry eye and other eye related diseases
